Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01065012 · ClinicalTrials.gov registry record · Phase 3
Treatment of Erectile Dysfunction - Long Term Safety and Efficacy
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,027
- Enrollment target
NCT01065012 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 1,027 participants.
The verdict
NCT01065012, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,027 participants
- Enrollment target
Study Summary
Open-Label Phase 3 study to evaluate the long-term safety and efficacy of udenafil, an orally administered selective inhibitor of PDE-5 for the treatment of subjects with erectile dysfunction (ED).
Interventions
- DRUG Udenafil 50 mg
- DRUG Udenafil 100 mg
- DRUG Udenafil 150 mg
- DRUG Placebo Matching 50 mg Udenafil
- DRUG Placebo Matching 100 mg Udenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,027 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01065012
The ClinicalTrials.gov registry entry for NCT01065012 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,027 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Udenafil 50 mg is the first listed.
NCT01065012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01065012 about?
NCT01065012 is a clinical study titled "Treatment of Erectile Dysfunction - Long Term Safety and Efficacy". Open-Label Phase 3 study to evaluate the long-term safety and efficacy of udenafil, an orally administered selective inhibitor of PDE-5 for the treatment of subjects with erectile dysfunction (ED).
What is the current status of trial NCT01065012?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,027 participants. The study started on 2010-01. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01065012?
The interventions under investigation include: Udenafil 50 mg (DRUG), Udenafil 100 mg (DRUG), Udenafil 150 mg (DRUG), Placebo Matching 50 mg Udenafil (DRUG), Placebo Matching 100 mg Udenafil (DRUG).
Who is sponsoring clinical trial NCT01065012?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.